Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
United States
Sarah Cannon Research Institute at HealthONE, Denver, Colorado Smilow Cancer Hospital at Yale New Haven Breast Center, New Haven, Connecticut Community Cancer Center North, Indianapolis, Indiana SCRI Oncology Partners, Nashville, Tennessee The University of Texas MD Anderson Cancer Center, Houston, Texas